DHR
$189.35-0.76 (-0.40%)
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Recent News
Is Danaher Corporation (DHR) A Good Stock To Buy Now?
Is DHR a good stock to buy? We came across a bullish thesis on Danaher Corporation on Buffett_N_Me’s Substack. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation’s share was trading at $190.11 as of March 19th. DHR’s trailing and forward P/E were 37.80 and 22.52 respectively according to Yahoo Finance. Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internat
IDBS Award Highlights Danaher’s Growing Biopharma Software And Recurring Revenue Story
IDBS, a Danaher company, received the Best Biologics Digitalisation: Software Innovation Award at the 2026 Asia Pacific Biopharma Excellence Awards. The recognition highlights IDBS’s role in biopharma digitalisation across the Asia Pacific region. The award draws attention to Danaher’s growing cloud software presence within its broader life sciences portfolio. For investors watching NYSE:DHR, this award puts a spotlight on a part of Danaher’s business that sits away from traditional...
1 S&P 500 Stock Worth Your Attention and 2 Facing Headwinds
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Oxford Nanopore Technologies Conference: Clinical Sales Surge as Growth Targets Reset, Break-Even Delayed
Oxford Nanopore Technologies (LON:ONT) Chief Financial Officer Nick Keher outlined the company’s progress in expanding beyond its historically research-led revenue base, highlighting rapid growth in clinical and applied industrial end markets, continued investment in regulated diagnostics pathways,
Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”
Agilent Technologies, Inc. (NYSE:A) is one of the stocks on which Jim Cramer expressed his thoughts. A caller asked if the stock will ever come back, and here’s what Cramer had to say in response: You know, they do so much test and measurement that is biotech. It’s almost like a Danaher, which stopped working. […]